Security
Voyager Therapeutics, Inc. Common Stock · VYGR
VYGRNASDAQCommon stockCurrentCIK 1640266Updated Nov 6, 2026
VYGR price & chart
Loading TradingView…
NASDAQ:VYGR on TradingView ↗About the company
Voyager Therapeutics, Inc. (Nasdaq: VYGR) is a biotechnology company dedicated to leveraging the power of human genetics to modify the course of - and ultimately cure - neurological diseases. Our pipeline includes programs for Alzheimer’s disease, Friedreich’s ataxia, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and multiple other diseases of the central nervous system. Many of our programs are derived from our TRACER™ AAV capsid discovery platform, which we have used to generate novel capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Some of our programs are wholly owned, and some are advancing with partners including Alexion, AstraZeneca Rare Disease; Novartis Pharma AG; and Neurocrine Biosciences, Inc. For more information, visit http://www.voyagertherapeutics.com.
In the news
Recent filings
Completion of Acquisition or Disposition of Assets
Items 2.01
10-Q filing
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02, 9.01
SCHEDULE 13G/A - filed by ARMISTICE CAPITAL, LLC regarding Voyager Therapeutics, Inc.
Results of Operations and Financial Condition
Items 2.02, 9.01
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 288,311,000Source | 426,041,000Source | 197,753,000Source | 322,101,000Source | 436,225,000Source | 219,325,000Source | 353,240,000Source | 469,592,000Source | 252,281,000Source | 393,050,000Source | 351,281,000Source | 159,356,000Source |
| Property, Plant and Equipment, NetUSD | 13,291,000Source | 15,201,000Source | 11,194,000Source | 13,919,000Source | 16,267,000Source | 12,218,000Source | 13,929,000Source | 17,381,000Source | 13,136,000Source | 14,314,000Source | 16,494,000Source | 17,857,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 45,125,000Source | 112,525,000Source | 35,769,000Source | 43,940,000Source | 76,127,000Source | 43,314,000Source | 74,755,000Source | 143,078,000Source | 65,300,000Source | 71,367,000Source | 68,802,000Source | 98,959,000Source |
| Assets, CurrentUSD | 219,585,000Source | 373,443,000Source | 125,228,000Source | 227,889,000Source | 381,570,000Source | 146,981,000Source | 245,206,000Source | 409,137,000Source | 202,687,000Source | 276,809,000Source | 319,684,000Source | 124,499,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 6,618,000Source | 8,415,000Source | 5,736,000Source | 9,771,000Source | 7,298,000Source | 3,857,000Source | 7,077,000Source | 6,112,000Source | 4,328,000Source | 7,945,000Source | 5,318,000Source | 5,394,000Source |
| Operating Lease, Right-of-Use AssetUSD | 29,740,000Source | 34,523,000Source | 25,905,000Source | 30,973,000Source | 35,514,000Source | 27,209,000Source | 32,128,000Source | 39,204,000Source | 28,478,000Source | 33,349,000Source | 13,510,000Source | 15,485,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 68,486,000Source | 95,731,000Source | 43,376,000Source | 78,157,000Source | 100,808,000Source | 45,656,000Source | 80,538,000Source | 128,706,000Source | 56,200,000Source | 93,290,000Source | 114,961,000Source | 100,336,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 56,000Source | 55,000Source | 61,000Source | 56,000Source | 54,000Source | 60,000Source | 55,000Source | 54,000Source | 59,000Source | 55,000Source | 44,000Source | 38,000Source |
| Additional Paid in CapitalUSD | 638,241,000Source | 621,985,000Source | 653,052,000Source | 634,696,000Source | 618,538,000Source | 647,714,000Source | 630,051,000Source | 613,850,000Source | 641,895,000Source | 626,296,000Source | 497,506,000Source | 452,713,000Source |
| Retained Earnings (Accumulated Deficit)USD | -418,479,000Source | -291,697,000Source | -498,315,000Source | -390,587,000Source | -282,653,000Source | -473,842,000Source | -357,205,000Source | -272,512,000Source | -445,905,000Source | -326,184,000Source | -261,182,000Source | -393,512,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 7,000Source | -33,000Source | -421,000Source | -221,000Source | -522,000Source | -263,000Source | -199,000Source | -506,000Source | 32,000Source | -407,000Source | -48,000Source | -219,000Source |
| Stockholders' Equity Attributable to ParentUSD | 219,825,000Source | 330,310,000Source | 154,377,000Source | 243,944,000Source | 335,417,000Source | 173,669,000Source | 272,702,000Source | 340,886,000Source | 196,081,000Source | 299,760,000Source | 236,320,000Source | 59,020,000Source |
| Liabilities and EquityUSD | 288,311,000Source | 426,041,000Source | 197,753,000Source | 322,101,000Source | 436,225,000Source | 219,325,000Source | 353,240,000Source | 469,592,000Source | 252,281,000Source | 393,050,000Source | 351,281,000Source | 159,356,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 35,495,000Source | 44,210,000Source | 16,685,000Source | 41,983,000Source | 40,130,000Source | 17,453,000Source | 40,212,000Source | 72,553,000Source | 26,541,000Source | 49,788,000Source | 64,508,000Source | 72,591,000Source |
| Operating Lease, Liability, CurrentUSD | 7,848,000Source | 6,979,000Source | 6,876,000Source | 7,637,000Source | 6,736,000Source | 7,363,000Source | 7,430,000Source | 5,940,000Source | 7,840,000Source | 7,227,000Source | 3,200,000Source | 2,832,000Source |
| Accounts Payable, CurrentUSD | 2,116,000Source | 3,160,000Source | 1,614,000Source | 1,804,000Source | 2,605,000Source | 2,723,000Source | 2,634,000Source | 7,579,000Source | 5,013,000Source | 3,996,000Source | 1,604,000Source | 2,566,000Source |
| Operating Lease, Liability, NoncurrentUSD | 30,520,000Source | 38,368,000Source | 25,691,000Source | 32,567,000Source | 40,205,000Source | 27,203,000Source | 34,566,000Source | 41,995,000Source | 28,659,000Source | 36,499,000Source | 17,093,000Source | 20,294,000Source |
| Other Liabilities, NoncurrentUSD | — | 39,368,000Source | — | — | 41,205,000Source | — | — | 42,996,000Source | — | 37,499,000Source | 18,094,000Source | 21,295,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 14,953,000Source | 11,442,000Source | 7,951,000Source | 12,025,000Source | 10,273,000Source | 6,972,000Source | 9,053,000Source | 7,595,000Source | 12,098,000Source | 14,171,000Source | 16,823,000Source | 7,816,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 229,000,000Source | 345,400,000Source | 148,800,000Source | 262,000,000Source | 371,000,000Source | 171,700,000Source | 295,100,000Source | 400,500,000Source | 201,700,000Source | 332,400,000Source | 230,900,000Source | 118,800,000Source |
| Other Assets, Noncurrent | — | — | —Source | — | — | — | — | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -27,937,000Source | -31,021,000Source | -119,721,000Source | -65,002,000Source | 132,330,000Source | -46,408,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 2,488,000Source | 3,673,000Source | 14,787,000Source | 14,785,000Source | 11,153,000Source | 9,344,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | -267,000Source | 119,000Source | 257,000Source | -78,646,000Source | 80,150,000Source | — |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | -2,290,000Source | -1,362,000Source | 1,017,000Source | 2,392,000Source | -962,000Source | 1,992,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -33,419,000Source | -37,895,000Source | -132,467,000Source | -15,310,000Source | 77,919,000Source | -12,509,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 8,101,000Source | 41,201,000Source | 125,446,000Source | -94,859,000Source | -141,643,000Source | -7,339,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 14,000Source | 658,000Source | 2,596,000Source | 3,521,000Source | 3,256,000Source | 2,491,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 3,332,000Source | 82,000Source | 816,000Source | 114,015,000Source | 33,645,000Source | 1,110,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -21,986,000Source | 3,388,000Source | -6,205,000Source | 3,846,000Source | -30,079,000Source | -18,738,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 50,739,000Source | 115,399,000Source | 38,505,000Source | 46,814,000Source | 46,050,000Source | 77,629,000Source | 68,036,000Source | 74,241,000Source | 70,395,000Source | 100,474,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 714,000Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 3,460,000Source | 3,434,000Source | 2,433,000Source | 4,133,000Source | 2,488,000Source | 3,673,000Source | 14,787,000Source | 14,785,000Source | 11,153,000Source | 9,344,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | 229,000,000Source | 345,400,000Source | 148,800,000Source | 262,000,000Source | 171,700,000Source | 295,100,000Source | 201,700,000Source | 332,400,000Source | 230,900,000Source | 118,800,000Source |
| DepreciationUSD | — | — | — | — | — | — | 932,000Source | 1,014,000Source | 4,060,000Source | 4,731,000Source | 4,441,000Source | 6,191,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | — | -30,000Source | -141,000Source | -510,000Source | -178,000Source | -377,000Source |
| Gain (Loss) on Termination of LeaseUSD | — | — | — | — | — | — | — | — | — | — | — | 2,468,000Source |
| General and Administrative ExpenseUSD | — | — | 8,093,000Source | 8,168,000Source | 7,516,000Source | 10,495,000Source | 8,261,000Source | 9,640,000Source | 37,544,000Source | 35,920,000Source | 35,822,000Source | 30,980,000Source |
| Income Tax Expense (Benefit)USD | — | — | 83,000Source | 43,000Source | 20,000Source | 15,000Source | 14,000Source | 37,000Source | 144,000Source | 665,000Source | 1,408,000Source | 16,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -27,892,000Source | -9,044,000Source | -24,473,000Source | -33,382,000Source | -27,937,000Source | -31,021,000Source | -119,721,000Source | -65,002,000Source | 132,330,000Source | -46,408,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | -9,044,000Source | — | — | — | — | -119,721,000Source | -65,002,000Source | 132,330,000Source | -46,408,000Source |
| Nonoperating Income (Expense)USD | — | — | 2,785,000Source | 4,779,000Source | 1,939,000Source | 3,258,000Source | 2,347,000Source | 3,709,000Source | 12,267,000Source | 18,950,000Source | 11,724,000Source | 4,445,000Source |
| Operating ExpensesUSD | — | — | 43,959,000Source | 38,409,000Source | 29,557,000Source | 41,825,000Source | 32,863,000Source | 41,166,000Source | 172,218,000Source | 163,288,000Source | 127,994,000Source | 91,744,000Source |
| Operating Lease, ExpenseUSD | — | — | 1,900,000Source | 1,900,000Source | 1,800,000Source | 1,900,000Source | 1,900,000Source | 1,900,000Source | 7,500,000Source | 10,000,000Source | 3,600,000Source | 4,600,000Source |
| Operating Lease, Impairment LossUSD | — | — | — | — | — | — | — | — | — | 2,776,000Source | — | — |
| Operating Lease, Lease IncomeUSD | — | — | 303,000Source | 199,000Source | — | 303,000Source | — | 440,000Source | — | 601,000Source | — | 1,380,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 400,000Source | 200,000Source | 411,000Source | 427,000Source | 435,000Source | 418,000Source | 1,649,000Source | 622,000Source | 3,000Source | 2,653,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | 3,038,000Source | — | — | 93,473,000Source | — | — |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 294,000Source | 82,000Source | 267,000Source | 388,000Source | 1,852,000Source | 629,000Source |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 13,365,000Source | 24,629,000Source | 3,165,000Source | 5,200,000Source | 2,593,000Source | 6,473,000Source | 40,374,000Source | 80,001,000Source | 250,008,000Source | 40,907,000Source |
| Operating Income (Loss)USD | — | — | -30,594,000Source | -13,780,000Source | -26,392,000Source | -36,625,000Source | -30,270,000Source | -34,693,000Source | -131,844,000Source | -83,287,000Source | 122,014,000Source | -50,837,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 400,000Source | 200,000Source | 411,000Source | 427,000Source | 435,000Source | 418,000Source | 1,649,000Source | 622,000Source | 3,000Source | 2,653,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -27,809,000Source | -9,001,000Source | -24,453,000Source | -33,367,000Source | -27,923,000Source | -30,984,000Source | -119,577,000Source | -64,337,000Source | 133,738,000Source | -46,392,000Source |
| Income Tax Expense (Benefit)USD | — | — | 83,000Source | 43,000Source | 20,000Source | 15,000Source | 14,000Source | 37,000Source | 144,000Source | 665,000Source | 1,408,000Source | 16,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -27,892,000Source | -9,044,000Source | -24,473,000Source | -33,382,000Source | -27,937,000Source | -31,021,000Source | -119,721,000Source | -65,002,000Source | 132,330,000Source | -46,408,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.47Source | -0.16Source | -0.4Source | -0.57Source | -0.47Source | -0.53Source | -2.04Source | -1.13Source | 3.08Source | -1.21Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.47Source | -0.16Source | -0.4Source | -0.57Source | -0.47Source | -0.53Source | -2.04Source | -1.13Source | 2.97Source | -1.21Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 58,803,015Source | 57,851,110Source | 60,547,863Source | 58,666,460Source | 59,496,329Source | 58,349,769Source | 58,691,136Source | 57,667,543Source | 43,020,747Source | 38,356,810Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 58,803,015Source | 57,851,110Source | 60,547,863Source | 58,666,460Source | 59,496,329Source | 58,349,769Source | 58,691,136Source | 57,667,543Source | 44,569,334Source | 38,356,810Source |
| Additional Financial Items | ||||||||||||
| General and Administrative ExpenseUSD | — | — | 8,093,000Source | 8,168,000Source | 7,516,000Source | 10,495,000Source | 8,261,000Source | 9,640,000Source | 37,544,000Source | 35,920,000Source | 35,822,000Source | 30,980,000Source |
| Interest Income (Expense), Nonoperating, NetUSD | — | — | 2,385,000Source | 4,579,000Source | 1,528,000Source | 2,831,000Source | 1,912,000Source | 3,291,000Source | 10,618,000Source | 18,328,000Source | 11,721,000Source | 1,792,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | -9,044,000Source | — | — | — | — | -119,721,000Source | -65,002,000Source | 132,330,000Source | -46,408,000Source |
| Nonoperating Income (Expense)USD | — | — | 2,785,000Source | 4,779,000Source | 1,939,000Source | 3,258,000Source | 2,347,000Source | 3,709,000Source | 12,267,000Source | 18,950,000Source | 11,724,000Source | 4,445,000Source |
| Operating ExpensesUSD | — | — | 43,959,000Source | 38,409,000Source | 29,557,000Source | 41,825,000Source | 32,863,000Source | 41,166,000Source | 172,218,000Source | 163,288,000Source | 127,994,000Source | 91,744,000Source |
| Operating Lease, ExpenseUSD | — | — | 1,900,000Source | 1,900,000Source | 1,800,000Source | 1,900,000Source | 1,900,000Source | 1,900,000Source | 7,500,000Source | 10,000,000Source | 3,600,000Source | 4,600,000Source |
| Operating Lease, Lease IncomeUSD | — | — | 303,000Source | 199,000Source | — | 303,000Source | — | 440,000Source | — | 601,000Source | — | 1,380,000Source |
| Research and Development ExpenseUSD | — | — | 35,866,000Source | 30,241,000Source | 22,041,000Source | 31,330,000Source | 24,602,000Source | 31,526,000Source | 134,674,000Source | 127,368,000Source | 92,172,000Source | 60,764,000Source |
Filing attachments
vygr-ex99_1.htm · 8-K · 2026-11-05
Voyager Reports Third Quarter 2026 Financial and Operating Results - VY7523 clinical data readout on track for Q4 2026 and VY1706 dosing expected in the next few months pending enrollment - - Neurocrine Biosciences partnered Friedreich’s ataxia gene therapy program expected to enter the clinic in the coming months - - Ended Q3 2026 with cash position of $132 million, runway into Q2 2028 - LEXINGTON, Mass., November 5, 2026 -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company…
Read attachment ↗vygr-ex99_1.htm · 8-K · 2026-08-06
EX-99.1 2 vygr-ex99_1.htm EX-99.1 EX-99.1 Voyager Reports Second Quarter 2026 Financial and Operating Results - VY7523 clinical data and VY1706 clinical entry, both in Alzheimer’s, expected Q4 2026 - - Ended Q2 2026 with cash position of $149 million, runway into 2028 - LEXINGTON, Mass., August 6, 2026 -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today reported second quarter 2026 financial and oper…
Read attachment ↗ex991.htm · SCHEDULE 13G/A · 2026-05-15
EXHIBIT 99.1 AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13D OR 13G The undersigned agree to file jointly with the Securities and Exchange Commission (the “SEC”) any and all statements on Schedule 13D or Schedule 13G or Forms 3, 4 or 5(and any amendments or supplements thereto) required under section 13(d) and 16(a) of the Securities Exchange Act of 1934, as amended, in connection with purchases by the undersigned of the securities of any issuer. For that purpose, the undersigne…
Read attachment ↗vygr-20260507xex99d1.htm · 8-K · 2026-05-07
EX-99.1 2 vygr-20260507xex99d1.htm EX-99.1 EXHIBIT 99.1 Voyager Reports First Quarter 2026 Financial and Operating Results - VY1706 and NBIB-‘233 completed IND-enabling GLP toxicology; clinical entry expected H2 2026 - - Multiple presentations at ASGCT 2026, including late breaker on VY1706 3-month GLP tox data - - Ended Q1 2026 with cash position of $172 million, runway into 2028 - LEXINGTON, Mass., May 7, 2026 -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedic…
Read attachment ↗vygr-20260309xex99d1.htm · 8-K · 2026-03-09
EX-99.1 2 vygr-20260309xex99d1.htm EX-99.1 EXHIBIT 99.1 Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results - Transformative year for tau in AD: VY1706 clinical entry and VY7523 clinical data anticipated H2 2026 - - Validating brain-targeted capsids in humans: expect two I.V.-delivered neuro gene therapies to enter clinic H2 2026 - - Advancing Voyager NeuroShuttle™: murine study using anti-amyloid antibody supports sustained brain exposure profile - - Ended…
Read attachment ↗ex991.htm · SCHEDULE 13G/A · 2026-02-17
EXHIBIT 99.1 AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13D OR 13G The undersigned agree to file jointly with the Securities and Exchange Commission (the “SEC”) any and all statements on Schedule 13D or Schedule 13G or Forms 3, 4 or 5(and any amendments or supplements thereto) required under section 13(d) and 16(a) of the Securities Exchange Act of 1934, as amended, in connection with purchases by the undersigned of the securities of any issuer. For that purpose, the undersigne…
Read attachment ↗